Description
Disease Indications
Hereditary angioedema (HAE)
Manufacturer
Shire Pharmaceuticals
Usage
Subcutaneous
Medicine approved by
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Takhzyro (lanadelumab)
Price range: $9,000.00 through $40,000.00
Takhzyro (lanadelumab) is a medicine for the prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. It is available as solution for injection in single-dose, ready-to-use vial.
Additional information
| Package Single vial | 150 mg solution for injection, 300 mg solution for injection, 300 mg solution for injection x 2, 300 mg solution for injection x 6 |
|---|
Related products
-
Taltz (ixekizumab)
Price range: $1,500.00 through $3,000.00 Select options This product has multiple variants. The options may be chosen on the product page -
Olumiant (baricitinib)
Price range: $1,000.00 through $1,600.00 Select options This product has multiple variants. The options may be chosen on the product page -
Skilarence (dimethyl fumarate)
Price range: $150.00 through $250.00 Select options This product has multiple variants. The options may be chosen on the product page -
Cibinqo (abrocitinib)
Price range: $500.00 through $1,600.00 Select options This product has multiple variants. The options may be chosen on the product page
Reviews
There are no reviews yet.